thalidomide has been researched along with Dermatitis Exfoliativa in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of toxic pustuloderma secondary to thalidomide in a patient with severe nodular prurigo." | 3.69 | Thalidomide-induced toxic pustuloderma. ( Basarab, T; Darvay, A; Russell-Jones, R, 1997) |
| "In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors." | 2.53 | Paraneoplastic Itch Management. ( Rowe, B; Yosipovitch, G, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, X | 1 |
| Huang, C | 1 |
| Feng, Y | 1 |
| Xia, J | 1 |
| Zhang, M | 1 |
| Yin, Z | 1 |
| Chen, X | 1 |
| Wang, S | 1 |
| Mugheddu, C | 1 |
| Pizzatti, L | 1 |
| Sanna, S | 1 |
| Atzori, L | 1 |
| Rongioletti, F | 1 |
| Krishnamoorthy, G | 1 |
| Kotecha, A | 1 |
| Pimentel, J | 1 |
| Rowe, B | 1 |
| Yosipovitch, G | 1 |
| Rose, AE | 1 |
| Patel, U | 1 |
| Chu, J | 1 |
| Patel, R | 1 |
| Meehan, S | 1 |
| Latkowski, JA | 1 |
| Bielsa, I | 1 |
| Teixidó, J | 1 |
| Ribera, M | 1 |
| Ferrándiz, C | 1 |
| Darvay, A | 1 |
| Basarab, T | 1 |
| Russell-Jones, R | 1 |
2 reviews available for thalidomide and Dermatitis Exfoliativa
| Article | Year |
|---|---|
Paraneoplastic Itch Management.
Topics: Acantholysis; Acanthosis Nigricans; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Apre | 2016 |
Erythrodermic lichen planus.
Topics: Aged; Chills; Dermatitis, Exfoliative; Glucocorticoids; Humans; Immunologic Factors; Itraconazole; L | 2011 |
6 other studies available for thalidomide and Dermatitis Exfoliativa
| Article | Year |
|---|---|
Apremilast for the treatment of papuloerythroderma of Ofuji.
Topics: Dermatitis, Exfoliative; Humans; Skin Diseases, Papulosquamous; Thalidomide | 2023 |
Case of erythrodermic lichen planus successful treated with thalidomide monotherapy.
Topics: Administration, Oral; Dermatitis, Exfoliative; Humans; Lichen Planus; Male; Middle Aged; Skin; Thali | 2020 |
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Critical | 2020 |
Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Exfoliative; Humans; Male; Middle Aged; Pruritu | 2019 |
Erythroderma due to thalidomide: report of two cases.
Topics: Adult; Dermatitis, Exfoliative; Drug Eruptions; Eosinophilia; Female; Humans; Kidney Failure, Chroni | 1994 |
Thalidomide-induced toxic pustuloderma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Exfoliative; Drug Eruptions; Female; Hum | 1997 |